Company Overview and News

19
Investments In The Booming Marijuana Sector, But Should You Dive In?

2018-09-21 seekingalpha - 3
The market for cannabis stocks is quite tumultuous and difficult to navigate. But just a year ago, options for ordinary retail investors were extremely limited; there were no ETFs to invest in, and most stocks were listed in Canada. But now, we have many choices as money has poured into stocks and funds in anticipation of Canada’s pending legalization of recreational cannabis on October 17 and growing speculation that other industries will buy in.
IMBBY PM MJ JAPAF UVV 2914 MJX UVVZP BATS 4162 ITYBF ACT CGC TLRY CMG VGR GWPH HMLSF JAPAY ETFC GWP IMBBF MO

2
What FDA's Stance on E-Cigarettes Means for Tobacco Stocks

2018-09-17 zacks
The e-cigarettes arena in the tobacco space has been in the spotlight since the past few days, thanks to FDA’s latest moves to curb the rave of such products among the youth. The FDA has issued a series of actions and directives for companies manufacturing e-cigarettes. In response to the recent legal enactments surrounding e-cigarettes, Altria (MO - Free Report) has applied for the review of smokeless tobacco product — Copenhagen Snuff.
IMBBY VGR JAPAF JAPAY 2914 BATS 4162 ITYBF IMBBF

9
2 Undervalued High-Yield Blue Chips You'll Want To Own During The Next Recession

2018-09-13 seekingalpha
High-yield blue chips are a favorite of conservative income investors, including retirees looking to live off dividends.
PM JAPAF JAPAY 2914 BATS 4162

13
FDA proposed crackdown on flavored e-cigs puts Juul on notice

2018-09-12 channelnewsasia
The U.S. Food and Drug Administration is considering a ban on flavored e-cigarettes from Juul Labs and other companies as it grapples with an "epidemic" of youth e-cigarette use that threatens to create a new generation of nicotine addicts, the agency's head said on Wednesday.
WFCNP PM JAPAF BATS ITYBF 4162 JAPAY MO WFC IMBBY 2914 IMBBF

13
US FDA considers ban on flavored e-cigarettes to protect minors

2018-09-12 channelnewsasia
The U.S. Food and Drug Administration is considering a ban on flavored e-cigarettes in response to an "epidemic" of young people using e-cigarettes, the agency's leader said on Wednesday.
WFCNP PM JAPAF BATS ITYBF 4162 JAPAY MO WFC IMBBY 2914 IMBBF

10
Big Tobacco’s global reach on social media

2018-09-01 sfgate - 1
It has been years since the tobacco industry promised to stop luring young people to smoke cigarettes.
IMBBY PM JAPAF JAPAY 2914 BATS 4162 ITYBF NYTAB IMBBF

1
Tokyo stocks turn lower in thin trading

2018-08-20 japantimes.co.jp
Stocks fell back on the Tokyo Stock Exchange on Monday, as investors retreated to the sidelines amid a dearth of fresh trading incentives.
ITOCY JAPAF 2914 SFTBF JFEEF TOELY KDDIY SUOPY JAPAY ITOCF 5411 9984 SUMCF KDDIF 8035 TOELF SFTBY

1
British American Tobacco to raise prices in line with October tax hike

2018-08-20 japantimes.co.jp
British American Tobacco Japan has filed for approval from the Finance Ministry to raise its tobacco product prices in line with the planned tobacco tax hike on Oct. 1, informed sources said Monday.
JAPAF JAPAY 2914 BATS 4162

1
Japan Tobacco seeks approval for price hikes from Finance Ministry

2018-08-14 japantimes.co.jp
Japan Tobacco Inc. on Tuesday filed for Finance Ministry approval over its plans to raise the prices of most of its products in line with the tobacco tax hike set for Oct. 1.
JAPAF JAPAY 2914

10
Turkish lira crash may affect some Japanese companies with operations there

2018-08-14 japantimes.co.jp
Your next vacation in sun-drenched Turkey may now be a lot cheaper. On the flip side, corporate profits from selling goods locally are dwindling by the day when converted to home currencies.
PM JAPAF TM BNPQY DLAKF SCGLF JAPAY AREVA VVCTY HUGPF 7011 VCT MHVYF ITX VOD TAVHF VOD BOSSY SCGLY 2914 TYT BVA BNPQF TOYOF DDAIF TAVHY VLKAF BNPZY VODPF TCG 7203 DLAKY GLE

9
Japan Tobacco to buy Bangladesh firm for $1.5 billion

2018-08-07 japantimes.co.jp
Japan Tobacco Inc. has agreed to buy a Bangladeshi cigarette manufacturer for 124.3 billion taka ($1.5 billion), taking its acquisition strategy to one of Asia’s fastest-growing economies.
PM JAPAF JAPAY 2914

9
Japan Tobacco to Acquire Bangladesh Company for $1.5 Billion - Bloomberg

2018-08-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PM JAPAF JAPAY 2914

3
Deals of the day-Mergers and acquisitions

2018-08-06 reuters
Aug 6 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Monday:
BAMGF UBNC JAPAF TWX AGODY 2914 AMCRY TWC 532712 PGW FSUGY PGWFY AGO JAPAY RCOM FSUMF ATLGF FMG PGWFF BAMKF KOS BAM

1
Japan Tobacco 2018 Q2 - Results - Earnings Call Slides

2018-08-05 seekingalpha
The following slide deck was published by Japan Tobacco in conjunction with their 2018 Q2 earnings call.
JAPAF JAPAY 2914

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 006474535